Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $79 from $80 and keeps an Overweight rating on the shares. Halozyme has not yet scheduled a date to report Q3 earnings, but the firm continues to believe that strength in royalties and cost discipline will drive EPS outperformance for the remainder of 2025, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme’s Strong Royalty Revenue and Strategic Initiatives Justify Buy Rating Despite Potential Risks
- Halozyme’s Strong Financial Outlook and Strategic Investment Potential Amidst Policy Stability
- Halozyme upgraded at Leerink on lower-than-feared Part B exposure
- Halozyme upgraded to Market Perform from Underperform at Leerink
- Halozyme Confirms Minimal Impact from Medicare Guidance